Interview with Vicki St Quintin, COO, PIASA. Pharmaceutical Industry Association…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Address: Thornhill Office Park, Building No 5, 94 Bekker Street
Vorna Valley 1686, South Africa ,South Africa
Tel: +27 11 805 51 00
Web: http://www.piasa.co.za/default.asp
The Pharmaceutical Industry Association of South Africa (PIASA) is a trade association of companies involved in the manufacture and/or marketing of prescription medicines in South Africa.
Membership is voluntary and includes a broad representation of foreign multinational pharmaceutical companies and local companies, both large and small. PIASA currently represents approximately 33% of the total private sector pharmaceutical market in South Africa.
The members of PIASA aim to bring the best medicines to the South African market. PIASA companies are important members of the South African business community, marketing medicines, including both innovative and generic medicines, to the health professions. In addition to promoting and safeguarding the interests of members PIASA provides a service to the public as well as the general medical and healthcare community.
Mission
To sustain a favourable environment for the continued development of the pharmaceutical industry in South Africa as it strives to increase access to quality medicines, with the ultimate aim of saving lives and improving the quality of life for all South Africans
Values
Members of PIASA subscribe to the following values:
Respect for intellectual property rights
Commitment to good corporate governance
Commitment to the Code of Marketing Practice
Adherence to best practice in manufacturing, clinical research, distribution and regulatory affairs.
Profile
Pharmaceutical trade organisation – voluntary membership.
Members comprise research based multinational, local/generic and empowerment pharmaceutical companies operating in SA.
18 members
32% Private Sector Market Share
Represents South Africa internationally as a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
association
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
Africa accounts for 19 percent of the world’s population and one-quarter of the global disease burden. However, for a host of reasons – both real and perceptual – the continent…
Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold,…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
See our Cookie Privacy Policy Here
